Primary liver cancer is one of the most common malignant tumors in China and has been a major threat to human health.With advances in the basic and clinical research on primary liver cancer in recent years,the diagnosis and treatment methods for primary liver cancer have been constantly enriched.Traditional Chinese medicine(TCM)has played an important role in the diagnosis and treatment of primary liver cancer,but there is still a lack of standardized guidelines for syndrome differentiation-based treatment and response evaluation criteria.In order to further standardize the TCM diagnosis and treatment of primary liver cancer,the drafting group developed this guideline through literature review,expert interviews,questionnaire surveys,and consensus meetings based on the requirements of TCM standardization and related technical guidance documents,so as to provide a reference for clinicians.This guideline has been approved by China Association of Chinese Medicine,with the standard number of T/CACM1575—2024.

Fatty liver disease can be classified into alcoholic fatty liver disease and nonalcoholic fatty liver disease based on etiology,and it has become the most important liver disease worldwide.Due to the differences in the etiology and pathological mechanism of fatty liver disease,it may manifest as different traditional Chinese medicine syndromes during different pathological stages.The syndrome is based on the pathogenesis in a certain stage and is the basis for syndrome differentiation in traditional Chinese medicine.At present,there is still a lack of unified studies on the syndrome of fatty liver disease,and different methods for syndrome differentiation have obtained different syndrome types,which affects the syndrome differentiation-based treatment in clinical practice.This article briefly introduces the clinical studies on the syndrome types of fatty liver disease conducted by doctors of all dynasties and modern doctors and further emphasizes the significance of standard and accurate determination of the traditional Chinese medicine syndrome types of fatty liver disease in syndrome differentiation-based treatment.

Objective:To investigate the detection status and genotypes distribution characteristics of norovirus(NoV)in environmental sewage from three monitoring points in Fujian province, and to explore the significance of its application to NoV monitoring.Methods:Sewage samples were collected monthly at 5 sampling sites in representative monitoring cities, enriched and concentrated. Partial gene fragments of norovirus VP1 were amplified by reverse transcription-semi nested polymerase chain reaction (RT-snPCR), TA cloned and sequenced. Genotypes were identified based on the sequencing.Results:A total of 56 sewage samples were collected from July 2022 to June 2023. The detection rates of GⅠ and GⅡ were 89.29% (50/56) and 94.64% (53/56), respectively. A total of 7 NoV GⅠ genotypes and 13 GⅡgenotypes were identified. GⅠ.1, GⅠ.4, GⅡ.4 and GⅡ.17 were the dominant genotypes. NoV genotypes detected in different sampling sites were not exactly the same. The detection rate of NoV was low from August to November 2022, and the prevalence of the dominant genotypes was different in different seasons. GⅠ.1 and GⅡ.4 were highly prevalent from August to November 2022, but were replaced by GⅠ.4 and GⅡ.17 from December 2022 to June 2023, respectively. More NoV genotypes were detected in January-June 2023, comparing to the July-December 2022. The dominant genotype GII.17, has multiple clades and new variants have been discovered that are different from the 2014/2015 circulating strains.Conclusions:The detection rates of NoV in environmental sewage were very high, and genotypes were diverse. Environmental sewage surveillance could be an important complementary method for NoV cases surveillance.

Objective To analyze the clinical characteristics of children with hand,foot and mouth disease(HFMD)infected with different enterovirus subtypes and construct a risk nomogram prediction model to provide basis for HFMD prevention and treatment.Meth-ods The clinical data of 346 cases of children hospitalized with HFMD in Shanxi Children's Hospital(Shanxi Maternal and Child Health Hospital)from 2017-2021 were collected and divided into Coxsackie virus A16 group(n=26),enterovirus 71 group(n=56)and en-terovirus general group(n=264)according to different enteroviruses,and the clinical characteristics were compared between the three groups to construct a risk nomogram model in children with HFMD combined with brainstem encephalitis to validate the prediction effect of the model.Results The age of children with HFMD was mainly distributed between 1 and 3 years(81.21％),with a male to female ra-tio of 1.56∶1,with a primary peak of incidence in June to August and a secondary peak in October to November,with enterovirus 71 type infections predominating in 2017 and enterovirus general infections in 2018-2021.The differences were statistically significant in age,days of hospitalization,presence of fever,fever typing,days of fever duration,herpes,maculopapular rash,oral rash,knee rash,white blood cell,platelet count,C-reactive protein and procalcitonin among the three groups(P＜0.05).The occurrence of HFMD combined with brainstem encephalitis in children was positively correlated with longer days of hospitalization and fever duration,papular rash and en-terovirus 71 positivity,and negatively correlated with longer days of rash(P＜0.05).The nomogram model showed that the probability of occurrence of childhood HFMD combined with brainstem encephalitis was 85.6％,the area under the receiver operating characteristic curve was 0.860.The calibration curve showed that the actual probability was in good agreement with the predicted probability,and the decision curve showed that the net gain of the model essentially to the full threshold probability was obvious.Conclusion HFMD in chil-dren has obvious seasonality with double peaks,enterovirus general type is the dominant pathogen of HFMD in recent years,the clinical characteristics of infection with different enteroviruses are different,the risk nomogram model has good early prediction effect on HFMD combined with brainstem encephalitis in children,and has high clinical application value,which is important for the prevention,diagnosis and treatment of HFMD in children.

ObjectiveTo decipher the mechanism of Wenxiao powder in alleviating corticosterone-induced depression-like behaviors in mice. MethodMale ICR mice were randomized into normal， model， paroxetine （20 mg·kg^-1）， and low- and high-dose （3.27， 6.54 g·kg^-1， respectively） Wenxiao powder groups. The mice in normal and model groups received equal volume of saline. Other groups except the normal group were injected with corticosterone subcutaneously 0.5 h after gavage to induce depression. Mice were tested for depression-like behaviors after drug administration. Enzyme-linked immunosorbent assay （ELISA） was performed to measure the corticosterone content in the serum. Nissl staining was performed to observe the damage of hippocampal neurons. Immunofluorescence staining was employed to observe the expression of double cortin （DCX） in the dentate gyrus （DG） of the hippocampus. Western blot was employed to determine the expression of proteins in the brain-derived neurotrophic factor （BDNF）/tyrosine kinase receptor B （TrkB）/extracellular signal-regulated kinase （ERK）/cAMP-response element-binding protein （CREB） pathway in the hippocampus. ResultCompared with the normal group， the model group showed decreased sucrose preference rate， increased immobility time in the tail suspension test （P<0.01）， and reduced residence time in the central area of the open field and the total movement distance （P<0.05， P<0.01）. In addition， the modeling elevated the corticosterone level in the serum （P<0.01）， decreased the volume and intensified the nuclear staining of hippocampal neurons in the DG area， reduced the expression of DCX in the DG area， and down-regulated the protein levels of BDNF， phosphorylated （p）-TrkB， p-ERK， and p-CREB in the hippocampus （P<0.05， P<0.01）. Compared with the model group， low-dose Wenxiao powder improved the mouse behavivors in the sucrose preference， open field， and tail suspension tests （P<0.05， P<0.01）， and high-dose Wenxiao powder improved the behaviors in the sucrose preference and open field tests （P<0.05， P<0.01）. In addition， Wenxiao powder lowered the serum corticosterone level （P<0.01） and recovered the structure and morphology of neurons with obvious nuclei and presence of Nissl bodies in the DG area of the hippocampus. Moreover， Wenxiao powder at both doses promoted the expression of DCX in the DG area， and high-dose Wenxiao powder up-regulated the protein levels of BDNF， p-TrkB， p-ERK， and p-CREB in the hippocampus （P<0.05， P<0.01）. ConclusionWenxiao powder can alleviate corticosterone-induced depression-like behaviors and promote neurogenesis in mice possibly by activating the BDNF/TrkB/ERK/CREB signaling pathway.

ObjectiveTo explore the syndrome elements and evolving patterns of patients with hepatitis B virus-related acute on chronic liver failure （HBV-ACLF） at different stages. MethodsClinical information of 1,058 hospitalized HBV-ACLF patients， including 618 in the early stage， 355 in the middle stage， and 85 in the late stage， were collected from 18 clinical centers across 12 regions nationwide from January 1， 2012 to February 28， 2015. The “Hepatitis B-related Chronic and Acute Liver Failure Chinese Medicine Clinical Questionnaire” were designed to investigate the basic information of the patients， like the four diagnostic information （including symptoms， tongue， pulse） of traditional Chinese medicine （TCM）， and to count the frequency of the appearance of the four diagnostic information. Factor analysis and cluster analysis were employed to determine and statistically analyze the syndrome elements and patterns of HBV-ACLF patients at different stages. ResultsThere were 76 four diagnostic information from 1058 HBV-ACLF patients， and 53 four diagnostic information with a frequency of occurrence ≥ 5% were used as factor analysis entries， including 36 symptom information， 12 tongue information， and 5 pulse information. Four types of TCM patterns were identified in HBV-ACLF， which were liver-gallbladder damp-heat pattern， qi deficiency and blood stasis pattern， liver-kidney yin deficiency pattern， and spleen-kidney yang-deficiency pattern. In the early stage， heat （39.4%， 359/912） and dampness （27.5%， 251/912） were most common， and the pattern of the disease was dominated by liver-gallbladder damp-heat pattern （74.6%， 461/618）； in the middle stage， dampness （30.2%， 187/619） and blood stasis （20.7%， 128/619） were most common， and the patterns of the disease were dominated by liver-gallbladder damp-heat pattern （53.2%， 189/355）， and qi deficiency and blood stasis pattern （27.6%， 98/355）； and in the late stage， the pattern of the disease was dominated by qi deficiency （26.3%， 40/152） and yin deficiency （20.4%， 31/152）， and the patterns were dominated by qi deficiency and blood stasis pattern （36.5%， 31/85）， and liver-gallbladder damp-heat pattern （25.9%， 22/85）. ConclusionThere are significant differences in the distribution of syndrome elements and patterns at different stages of HBV-ACLF， presenting an overall trend of evolving patterns as "from excess to deficiency， transforming from excess to deficiency"， which is damp-heat → blood stasis → qi-blood yin-yang deficiency.

Objective:To systematically evaluate the efficacy of live Bifidobacterium preparations combined with entecavir in the treatment of hepatitis B virus-related cirrhosis.Methods:PubMed, Web of Science, CNKI, Wanfang, VIP, and other databases were searched electronically until October 2020. Randomized controlled clinical trials in the treatment of hepatitis B virus-related cirrhosis with live Bifidobacterium preparations combined with entecavir were included for statistical analysis. The relative risk ( RR) was used as the effect size for the count data. Measurement data were expressed as mean difference ( MD) or standardized mean difference ( SMD) to represent the effect size. 95% confidence intervals (95% CI) were calculated for each effect size. The I2 statistic and P-values were used to evaluate the heterogeneity of the included literature. The fixed effect model was used for analysis if I2≤50%, P > 0.1; otherwise, the random effect model was used for meta-analysis. Results:A total of 865 patients from nine studies were included. Among them, 434 cases were in the live Bifidobacterium preparation combined with the entecavir treatment group and 431 cases in the entecavir group. The results showed that compared with the entecavir group, the live bifidobacterium preparation combined with the entecavir treatment group had significantly reduced the four indicators of liver fibrosis: serum hyaluronic acid (HA) ( SMD = -1.87 ng/ml, 95% CI: -2.32 ~ 1.41, P < 0.01), laminin (LN) ( SMD = -1.62 ng/ml, 95% CI: -2.04 ~ 1.19, P < 0.01), type III procollagen peptide (PC-III) ( SMD = -0.98, 95% CI: -1.26 ~ 0.7, P < 0.01), type IIIcollagen (III-C) ( SMD = -1.14 ng/ml, 95% CI: -1.73 ~ 0.55, P < 0.01), portal vein diameter ( SMD = -0.91 mm, 95% CI: -1.27 ~ 0.55, P < 0.01) and spleen thickness ( MD = -3.26mm, 95% CI: -3.95 ~ 2.58, P < 0.01). However, there was no statistically significant difference in the negative conversion rate of hepatitis B virus DNA (HBV DNA) between the two groups of patients. Conclusion:Compared to the entecavir treatment group, the live Bifidobacterium preparation combined with entecavir showed apparent severity improvement and enhanced clinical efficacy in patients with hepatitis B virus-related cirrhosis.

Liver fibrosis is the common pathological process of chronic liver diseases caused by various etiologies such as viral hepatitis and alcoholism, and it can progress to liver cirrhosis and even liver cancer and seriously threatens human health. Traditional Chinese medicine (TCM) has the characteristics of multiple components, targets, and pathways in inhibiting the progression of liver fibrosis and promoting the reversal of liver fibrosis and thus has unique clinical efficacy. In recent years, great progress has been made in the experimental research on the anti-liver fibrosis potential of TCM, and related studies have found a variety of compound TCM prescriptions, single TCM medicine, and their effective constituents and revealed their potential mechanism of action from the cellular and molecular levels. In order to further clarify the advances in the experimental research on the anti-liver fibrosis potential of TCM, this article systematically reviews the research advances in the past five years from the aspects of experimental animal models for the anti-liver fibrosis potential of TCM, the mechanism of action of TCM in the treatment of liver fibrosis, and TCM research from animal experiments to clinical trials, so as to provide a reference for researchers and clinicians to develop and apply anti-liver fibrosis TCM drugs.

Hepatic fibrosis (HF) is a key stage in the progression of chronic hepatitis to liver cirrhosis and even liver cancer, and it is a dynamic and reversible pathological change. Studies have shown that integrated traditional Chinese and Western medicine therapy has a good therapeutic effect on HF and can delay or reverse the progression of this disease. This article summarizes the pathogenesis of HF and discusses the diagnosis of HF, traditional Chinese medicine and Western medicine therapies, and the path of integrated traditional Chinese and Western medicine therapy, so as to provide ideas for the basic research and clinical application of integrated traditional Chinese and western medicine in the prevention and treatment of HF.